Philips-Sponsored Clinical Study Demonstrates Significant Breakthrough for COPD Treatment

PhilipsRecently published advancements in pulmonary research suggest that the combination of non-invasive ventilation (NIV) and home oxygen therapy (HOT) can significantly prolong time to readmission or death for patients with chronic obstructive pulmonary disease (COPD) following a life-threatening respiratory event or exacerbation. The five-year, multi-center study resulted in prolonged median time to readmission or death by nearly three months, and improved patient health-related quality of life in the first six weeks.

"Patients with severe COPD and persistent hypercapnia have historically had limited therapy options available to them and outcomes have generally been poor," said Dr. Nicholas Hart, Professor and Clinical Director of Lane Fox Respiratory Service, St Thomas’ Hospital in London. "The trial suggests that combining home oxygen and home non-invasive ventilation therapy can reduce hospital readmissions while maintaining patients’ quality of life, which will drastically change the way we approach COPD treatment worldwide. We are looking forward to hopefully decreasing the mortality and readmission rates that result from severe COPD with further research."

The randomized clinical trial of 116 patients in the United Kingdom was co-sponsored by Royal Philips (NYSE: PHG; AEX: PHIA) and carried out by respiratory experts at St Thomas' Hospital in London. The results showed that the addition of home NIV prolonged the median time to readmission or death from 1.4 months to 4.3 months.

"This study shows that home noninvasive ventilation is a potent, therapeutic tool that clinicians can use to help keep patients with advanced COPD out of the hospital," said Dr. Teofilo Lee-Chiong Jr., Chief Medical Liaison at Philips. "We hope that this will, in turn, allow them to lead healthier and more active lives at home. These findings add considerably to our knowledge of this highly prevalent and debilitating respiratory disorder, and are expected to greatly influence how clinicians care for patients with COPD on long-term oxygen therapy."

Preliminary results from this trial were announced in September 2016 at the European Respiratory Society's International Congress in London, U.K. The final paper, entitled 'Effect of home non-invasive ventilation with oxygen therapy vs. oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: A randomized clinical trial', was published in the Journal of the American Medical Association after being presented at the American Thoracic Society International Conference (Washington DC, US, May 19 - 24).

In April 2017, another Philips-sponsored study demonstrated significant cost savings for payers and hospitals from reduced COPD readmission rates resulting from a multifaceted care program that included the use of AVAPS-AE, a proprietary mode of non-invasive ventilation in the Trilogy device. Philips' sponsorship of these studies is the latest in the company's continued commitment to pioneering the development of home NIV technologies and ultimately help COPD patients breathe easier.

Philips works every day to support COPD patients and help them improve their quality of life by offering a range of solutions, including advanced NIV therapies such as the DreamStation BiPAP AVAPS and S/T, BiPAP A40 (available outside the United States) and Trilogy. Today, Philips is enabling more efficient patient management with the expansion of its connected Trilogy and Care Orchestrator, now commercially available in North America. For additional information on Philips' solutions for sleep and respiratory care, follow @PhilipsResp or visit www.respironics.com.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 70,000 employees with sales and services in more than 100 countries.

Most Popular Now

AI Points the Way to Better Doctor-Patie…

A computer analysis of hundreds of thousands of secure email messages between doctors and patients found that most doctors use language that is too complex for their patients to understand...

Open Call DIGITAL-2021-DEPLOY-01-TWINS-H…

The development of digital twins in healthcare (DTH) has progressed substantially, profiting from advances in science and technology. In order to exploit their benefits in view of better prevention approaches...

Mayo Clinic Researchers Use AI, Biomarke…

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients...

Mjog by Livi Launches Remote Monitoring …

Mjog by Livi has launched a remote monitoring tool that will help GPs support and monitor people with depression through messages sent to their smartphones. The latest data from the Office...

Could EKGs Help Doctors use AI to Detect…

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI)...

Computer Model of Blood Enzyme

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an...

4.5 Million Euros in EU Funding for Saar…

This year, three computer scientists from Saarbrücken were awarded an "ERC Starting Grant" by the European Research Council. This award, endowed with 1.5 million euros each, is among the most...

2022 EU4Health Work Programme Adopted to…

Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for...

Five NHS Trusts in Surrey and Sussex to …

A consortium of NHS trusts that covers a population of circa 1.2 million will gain immediate access to important patient imaging, and will mobilise a regional workforce for patients, following...

Helping Cancer Patients Avoid Excessive …

A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to identify which patients with certain head and neck cancers would benefit from reducing the intensity of...

The Programme for the Union's Action in …

On 24 March 2021, Regulation (EU) 2021/522 of the European Parliament and of the Council1 was adopted as part of the Multiannual Financial Framework for the 2021-2027 period. That Regulation...

CliniSys Acquires HORIZON Lab Systems an…

CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world’s...